U.S. FDA issues warning letter to Aurobindo Pharma’s subsidiary Eugia Pharma
2 sources·Updated August 14, 2026
Covered by 2 sources
- Business Standard·3h agoUSFDA issues warning letter to Aurobindo Pharma's Telangana facility
Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on an ongoing basis
Read at Business Standard → - The Hindu Health·4h agoU.S. FDA issues warning letter to Aurobindo Pharma’s subsidiary Eugia Pharma
A formulation manufacturing unit of subsidiary Eugia Pharma Specialities near Hyderabad had earlier received four observations and an Official Action Indicated (OAI) status from the regulator
Read at The Hindu Health →